AEON Biopharma (AEON) Income Statement (2021 - 2026)
Income Statement report data from Mar 31, 2021 to Mar 31, 2026 for AEON Biopharma (AEON).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jul 21, 2023 | Jun 30, 2023 | Mar 31, 2023 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||||||||
Research And Development | 2.03M (+26.09%) | 1.61M (+168.33%) | 600K (-43.40%) | 1.06M (+27.71%) | 830K (-72.70%) | 3.04M (+213.40%) | 970K (-78.15%) | 4.44M (-22.51%) | 5.73M (-10.33%) | 6.39M (+307.01%) | 1.57M (-82.61%) | 9.03M (-1.95%) | 9.21M (+23.13%) | 7.48M | - | - | - | - | - |
Selling General And Administrative | 3.90M (+0.26%) | 3.89M (+101.55%) | 1.93M (-40.80%) | 3.26M (+4.15%) | 3.13M (+19.01%) | 2.63M (-13.49%) | 3.04M (-8.43%) | 3.32M (-28.60%) | 4.65M (-11.76%) | 5.27M (+397.17%) | 1.06M (-78.59%) | 4.95M (+28.91%) | 3.84M (+57.38%) | 2.44M | - | - | - | - | - |
Operating Expenses | 5.93M (+7.62%) | 5.51M (+121.29%) | 2.49M (-42.63%) | 4.34M (+843.48%) | 460K (-80.17%) | 2.32M (-42.29%) | 4.02M | -153.47M | 74M (-73.86%) | 284M (+10687.45%) | 2.63M (-81.17%) | 14M (+7.05%) | 13M (+31.69%) | 9.91M | - | - | - | - | - |
Depreciation And Amortization | 20K (-66.67%) | 60K | - | - | 20K (-71.43%) | 70K | - | - | 30K (+50.00%) | 20K | - | - | 30K | - | - | - | - | - | - |
Operating Income | |||||||||||||||||||
Operating Income | -5.93M (+7.62%) | -5.51M (+121.29%) | -2.49M (-42.63%) | -4.34M (+843.48%) | -460.00K (-80.17%) | -2.32M (-42.29%) | -4.02M | 153M | -74.15M (-73.86%) | -283.71M (+10687.45%) | -2.63M (-81.17%) | -13.97M (+7.05%) | -13.05M (+2563.27%) | -490.00K (+13.95%) | -430.00K (+10.26%) | -390.00K (-13.33%) | -450.00K (+12.50%) | -400.00K (+100.00%) | -200.00K |
Ebit | -5.93M (+7.62%) | -5.51M (+121.29%) | -2.49M (-42.63%) | -4.34M (+843.48%) | -460.00K (-80.17%) | -2.32M (-42.29%) | -4.02M | 153M | -74.15M (-73.86%) | -283.71M (+10687.45%) | -2.63M (-81.17%) | -13.97M (+7.05%) | -13.05M (+2563.27%) | -490.00K (+13.95%) | -430.00K (+10.26%) | -390.00K (-13.33%) | -450.00K (+12.50%) | -400.00K (+100.00%) | -200.00K |
EBITDA | -5.91M (+437.27%) | -1.10M (-75.77%) | -4.54M (-31.63%) | -6.64M (+1409.09%) | -440.00K (-95.90%) | -10.73M (+73.91%) | -6.17M | 164M | -74.12M (-73.87%) | -283.69M (+925.63%) | -27.66M (+80.90%) | -15.29M (+17.43%) | -13.02M | 1.88M (0.00%) | 1.88M (-32.13%) | 2.77M (-51.06%) | 5.66M | -4.03M | 6.32M |
Other Income / Expenses | |||||||||||||||||||
Interest Income | - | - | - | - | - | - | - | - | - | - | - | 200K (-88.24%) | 1.70M (+47.83%) | 1.15M (+721.43%) | 140K (+7.69%) | 130K (+550.00%) | 20K (-33.33%) | 30K (+200.00%) | 10K |
Net Interest Income | - | - | - | - | - | - | - | - | - | - | - | 200K (-88.24%) | 1.70M (+47.83%) | 1.15M (+721.43%) | 140K (+7.69%) | 130K (+550.00%) | 20K (-33.33%) | 30K (+200.00%) | 10K |
Other Non Operating Income | 30K (-89.66%) | 290K (+314.29%) | 70K (-22.22%) | 90K (-10.00%) | 100K (0.00%) | 100K (+400.00%) | 20K (-33.33%) | 30K (-25.00%) | 40K (-78.95%) | 190K (+1800.00%) | 10K (-80.00%) | 50K (-16.67%) | 60K (-57.14%) | 140K (-93.94%) | 2.31M (-26.90%) | 3.16M (-48.28%) | 6.11M | -3.63M | 6.52M |
Net Income | |||||||||||||||||||
Income Before Tax | -11.79M (-68.26%) | -37.14M (+718.06%) | -4.54M (-31.63%) | -6.64M | 9.10M (+337.50%) | 2.08M | -6.17M | 164M | -118.02M (-60.36%) | -297.71M (+976.32%) | -27.66M (+79.84%) | -15.38M (-12.81%) | -17.64M | 1.88M (0.00%) | 1.88M (-32.13%) | 2.77M (-51.06%) | 5.66M | - | - |
Income Tax Expense | - | - | - | - | - | - | - | - | - | - | - | 90K (-77.50%) | 400K (+66.67%) | 240K (+1100.00%) | 20K | - | - | - | - |
Net Income From Continuing Operations | -11.79M (-68.26%) | -37.14M (+718.06%) | -4.54M (-31.63%) | -6.64M | 9.10M (+337.50%) | 2.08M | -6.17M | 164M | -118.02M (-60.36%) | -297.71M (+976.32%) | -27.66M (+79.84%) | -15.38M (-12.81%) | -17.64M | 1.64M (-12.30%) | 1.87M (-32.49%) | 2.77M (-51.06%) | 5.66M | -4.03M | 6.32M |
Net Income | -11.79M (-68.26%) | -37.14M (+718.06%) | -4.54M (-31.63%) | -6.64M | 9.10M (+337.50%) | 2.08M | -6.17M | 164M | -118.02M (-60.36%) | -297.71M (+976.32%) | -27.66M (+79.84%) | -15.38M (-12.81%) | -17.64M | 1.64M (-12.30%) | 1.87M (-32.49%) | 2.77M (-51.06%) | 5.66M | -4.03M | 6.32M |